Achaogen announces first patient enrollment in a phase 3 clinical trial of plazomicin
Achaogen announced that the first patient has been enrolled in a Phase 3 clinical trial of plazomicin to treat infections caused by carbapenem-resistant Enterobacteriaceae. Achaogen's plazomicin program is funded in part with a contract from the BARDA for up to $103.8 million. September 17, 2014